• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Dermatology

Pimecrolimus effective first-line treatment for atopic dermatitis

byBrandon ChildsandCordelia Ross
March 23, 2015
in Dermatology, Pediatrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

 1. The majority of patients using pimecrolimus cream (PIM, 52.6%) or topical corticosteroids (TCS, 50.5%) for the treatment of mild to moderate atopic dermatitis were cleared of manifestations of the disease by week 3 of use.

2. No significant differences in adverse effects and safety or changes in immunity were seen between the PIM and TCS treatment groups. 

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Atopic dermatitis (eczema) is a chronic, inflammatory skin disease that affects up to 25% of all infants. TCS are typically used as first-line treatment, but many patients and parents are non-compliant due to fear of their potential side effects. Researchers of the current study sought to compare the safety and efficacy of TCS and PIM in the treatment of mild to moderate atopic dermatitis. PIM is a topical calcineurin inhibitor used as first line therapy for atopic dermatitis in sensitive skin areas. Results showed that a majority of patients in both groups were cleared of the disease by week 3 of treatment. Patients in the PIM group required a much smaller amount of subsequent steroid use for exacerbations and achieved similar results. No significant differences in adverse effects or impairment of humoral or cellular immunity were seen between groups. This study is limited by adverse effect analyses that were not adjusted for the multiplicity of comparisons. Nonetheless, these findings may influence pediatricians to use PIM as a first-line agent in the treatment of atopic dermatitis in patients whose parents may be hesitant to use TCS.

Click to read the study, published today in Pediatrics

Relevant Reading: Atopic dermatitis

RELATED REPORTS

#VisualAbstract: Topical Delgocitinib Cream is Super to Oral Alitretinoin Capsules in Adults with Severe Chronic Hand Eczema

Verona’s Ohtuvayre shows promise in the treatment and management of Chronic Obstructive Pulmonary Disease

Delgocitinib cream is effective and safe for the treatment of chronic hand eczema

In-Depth [randomized controlled trial]: A total of 2439 children, ages 3 to 12 months, with atopic dermatitis were randomized into low potency TCS or PIM treatment arms. Parents were instructed to use the allotted treatment cream until atopic dermatitis had cleared. The medication could be restarted if the disease returned, and the PIM group was told to start a TCS if an exacerbation was not controlled by the assigned treatment. Treatment success was defined as being clear or almost clear of the disease, and success was achieved at week 3 by 52.6% and 50.5% of patients in the PIM and TCS groups, respectively. At the end of the 5-year study period, 88.7% of the PIM group and 92.3% of the TCS group reached overall treatment success. Patients in the PIM group used TCSs for a median of 7 days vs. 178 days in the TCS group. The PIM group experienced significantly more episodes of bronchitis (p = .02), infected eczema (p < .001), impetigo (p = .045), and nasopharyngitis (p = .04). Similar increases in immunoglobulin levels and decreases in peripheral blood T and B lymphocytes at baseline to week 260 were seen in both groups and were considered normal when compared to historical controls.

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: corticosteroidsEczema
Previous Post

Low-dose gonadotropin ovulation induction superior to clomiphene

Next Post

Collaborative care may improve outcomes in childhood ADHD

RelatedReports

#VisualAbstract: Topical Delgocitinib Cream is Super to Oral Alitretinoin Capsules in Adults with Severe Chronic Hand Eczema
StudyGraphics

#VisualAbstract: Topical Delgocitinib Cream is Super to Oral Alitretinoin Capsules in Adults with Severe Chronic Hand Eczema

May 1, 2025
2 Minute Medicine Rewind May 20, 2019
Pharma

Verona’s Ohtuvayre shows promise in the treatment and management of Chronic Obstructive Pulmonary Disease

January 20, 2025
Pimecrolimus effective first-line treatment for atopic dermatitis
Chronic Disease

Delgocitinib cream is effective and safe for the treatment of chronic hand eczema

August 29, 2024
#VisualAbstract: Twice-Daily Delgocitinib Cream was Effective for Adults with Moderate-to-Severe Chronic Hand Eczema
StudyGraphics

#VisualAbstract: Twice-Daily Delgocitinib Cream was Effective for Adults with Moderate-to-Severe Chronic Hand Eczema

August 13, 2024
Next Post
Collaborative care may improve outcomes in childhood ADHD

Collaborative care may improve outcomes in childhood ADHD

Incidental findings common with breast imaging, often benign

2 Minute Medicine Rewind March 16 – March 22, 2015

Further evidence of link between antithyroid drugs in pregnancy and birth defects

Insufficient evidence to recommend screening for thyroid dysfunction in asymptomatic adults

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
  • Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.